Industry Risk/Reward Index - Small Market Size To Limit Drugmaker Opportunities - DEC 2017
BMI View: Latvia ' s pharmaceutical market will present few opportunities for innovative drugmakers, reflected in its score of 55.4 out of 100 in BMI ' s Innovative Pharmaceuticals Risk/Reward Index, ranking it 13 th in the region. While the market poses few risks from an industry point of view nor from a political and economic standpoint, the small size of the market will severely restrict revenue generation opportunities.
Latvia: Innovative Pharmaceuticals RRI - Global And Regional Rank
Regional Rank (out of 25): 13th
Latvia: Innovative Pharmaceuticals Risk/Reward Index Q1 2018 Note: Scores out of 100; higher score = lower risk. Source: BMI's Innovative Pharmaceuticals Risk/Reward Index
This article is part of our Central Europe & Baltic States coverage. To access this article subscribe now or sign up for free trial